RG

Ravinder Gupta

Director Director DIN 03092794
DIN 03092794 First appointment Jan 2006 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Past companies 2 historical roles
Total affiliations 2 Since Jan 2006
Shareholding value •••• Premium profile

About Ravinder Gupta

Data last updated:

Ravinder Gupta was a Director at Le-Mantus Pharmaceuticals Private Limited (2006–2010) and Director at Ecstasy Biotech Private Limited (2011–2012). The companies operate in Pharma and Chemicals.

DIN 03092794
Primary Designation Director
Industry Pharma
First Appointment 24 Jan 2006

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director24 Jan 20062006₹29.31 Cr (FY 2024)Active
Ecstasy Biotech Private Limited U24239DL2003PTC123968
Director01 Jan 20112003Active

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Le-Mantus Pharmaceuticals Private Limited
Ecstasy Biotech Private Limited
Premium access

Shareholding and investment profile for Ravinder Gupta

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Ravinder Gupta

Ravinder Gupta was first appointed on 24 Jan 2006 as Director at Le-Mantus Pharmaceuticals Private Limited. The most recent appointment on record is 01 Jan 2011 at Ecstasy Biotech Private Limited.

Ravinder Gupta held 2 earlier board appointments: Le-Mantus Pharmaceuticals Private Limited (Director, 24 Jan 2006 to 30 Jul 2010); Ecstasy Biotech Private Limited (Director, 01 Jan 2011 to 22 Feb 2012).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available